1-3 of 3
Christoph Driessen
Close
Sort by
Journal Articles

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma

Arnold Bolomsky, Juho J. Miettinen, Alina Malyutina, Andrej Besse, Julia Huber, Stefanie Fellinger, Helene Breid, Alun Parsons, Kristaps Klavins, J. Thomas Hannich, Stefan Kubicek, Jo Caers, Wolfgang Hübl, Martin Schreder, Niklas Zojer, Christoph Driessen, Jing Tang, Lenka Besse, Caroline A. Heckman, Heinz Ludwig
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4125–4139.
https://doi.org/10.1182/bloodadvances.2020003826
Published: 2021
Includes: Supplemental data
Journal Articles

Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma

Yu-Hsiu T. Lin, Gregory P. Way, Benjamin G. Barwick, Margarette C. Mariano, Makeba Marcoulis, Ian D. Ferguson, Christoph Driessen, Lawrence H. Boise, Casey S. Greene, Arun P. Wiita
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3214–3227.
https://doi.org/10.1182/bloodadvances.2019000303
Published: 2019
Includes: Supplemental data
Journal Articles

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors

Sondra Downey-Kopyscinski, Ellen W. Daily, Marc Gautier, Ananta Bhatt, Bogdan I. Florea, Constantine S. Mitsiades, Paul G. Richardson, Christoph Driessen, Herman S. Overkleeft, Alexei F. Kisselev
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2443–2451.
https://doi.org/10.1182/bloodadvances.2018016360
Published: 2018
Includes: Supplemental data